Abstract | BACKGROUND: RESULTS: A comprehensive review of PubMed, Medscape, and Cochrane databases between 1995 and 2015 was performed to identify available studies describing topical use of mTOR inhibitors in individuals with tuberous sclerosis complex. In most studies, topical mTOR inhibitor application proved to be effective in the treatment of skin lesions related to tuberous sclerosis complex. Facial angiofibromas were the target lesions in most instances. Few studies reported clinical improvement of hypomelanotic macules. These drugs directly address the molecular defect related to tuberous sclerosis complex manifestations. CONCLUSIONS:
|
Authors | Sergiusz Jóźwiak, Krzysztof Sadowski, Katarzyna Kotulska, Robert A Schwartz |
Journal | Pediatric neurology
(Pediatr Neurol)
Vol. 61
Pg. 21-7
(08 2016)
ISSN: 1873-5150 [Electronic] United States |
PMID | 27222056
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2016 Elsevier Inc. All rights reserved. |
Chemical References |
- Protein Kinase Inhibitors
- TOR Serine-Threonine Kinases
|
Topics |
- Animals
- Humans
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- TOR Serine-Threonine Kinases
(antagonists & inhibitors)
- Tuberous Sclerosis
(drug therapy, enzymology)
|